SIGNATERA™ - PERSONALIZED MOLECULAR
RESIDUAL DISEASE (MRD) TESTING
Personalized cancer monitoring at every stage of your care
Ordered by your healthcare team, Signatera™ uses a simple blood draw to detect tiny fragments of cancer DNA, giving you and your doctor more information from treatment through long-term follow-up.
Get information
Information to guide your care, at every step
Signatera™ is a personalized MRD test designed to provide clinical insight at different points along your care pathway.
Detect molecular residual disease
Identify whether there are signs of residual disease after surgery or therapy.
Guide treatment decisions
Help determine whether additional treatment may be beneficial after surgery.
Monitor treatment response
Gain further insights into how your cancer is responding to therapy over time.
Detect recurrence earlier
Identify signs that cancer may be returning, potentially earlier than standard of care tools.
Used across a wide range of cancers
Your healthcare provider can order Signatera™ for any solid tumor cancer. Signatera™ has also received Medicare coverage for the following specific indications:
Colorectal cancer
Stage II–IV and oligometastatic CRC, adjuvant & recurrence monitoring.
Breast cancer
Stage II–IV neoadjuvant; Stage IIb+ adjuvant & recurrence monitoring.
Bladder cancer
Muscle-invasive bladder cancer (MIBC), adjuvant & recurrence monitoring.
Lung cancer
Stage I–III non-small cell lung cancer (NSCLC), surveillance.
Ovarian cancer
Stage II–IV ovarian, fallopian tube, or peritoneal, adjuvant & monitoring.
Any solid tumor
Monitoring response to immune checkpoint inhibitor (ICI) therapy.
Coverage. In addition to Medicare, Natera works with most commercial insurance plans, and financial assistance is available for eligible patients. Our team can help.
Learn how Signatera™ works
Watch a short overview of how Signatera™ is designed to monitor for molecular residual disease and provide information throughout your care.
Designed specifically for you, based on your unique tumor
Signatera™ is custom-designed from your own tumor's DNA.
Personalized to your tumor
Your tumor sample is analyzed to identify DNA markers that are unique to your cancer.
Blood testing over time
A simple blood draw is used to look for those same markers in your bloodstream at different points in your care.
Results for your care team
Your healthcare team reviews your results alongside imaging and other tests to help guide your treatment plan.
Backed by extensive clinical research
Signatera™ has been studied in large clinical trials and evaluated across a broad range of cancer types. Research findings have been shared with the medical community through approximately 200 published studies, including in some of the most widely read medical journals in the world. Your healthcare provider may already be familiar with Signatera™ through this body of research.
Anj, living with breast cancer
Anj's care team uses Signatera™ to help monitor her cancer over time
Dr. James Duke, head & neck cancer patient
Signatera™ was used as part of Dr. Duke's monitoring during and after treatment
Amanda, after colorectal cancer treatment
Amanda's doctor uses Signatera™ to help keep her informed as she moves forward
Ordered by your healthcare provider
Signatera™ is ordered and managed entirely through your healthcare team.
Insurance & billing support
We work with most commercial plans and Medicare, with financial assistance for those eligible.
Questions? We're here
Our team can answer questions about the test and coverage.
Get more information
Learn more about Signatera™
Get information to help you understand whether Signatera™ may be appropriate for your care. Complete the form and our team will follow up.
Frequently Asked Questions
Common questions about Signatera™
Signatera™ is a personalized blood test that looks for small amounts of cancer DNA in your body. It is custom-designed using your tumor to track changes over time and provide additional information to you and your healthcare team.
Signatera™ is designed for patients with solid tumor cancers. Your healthcare provider will determine if it is appropriate for your individual situation.
No. Signatera™ must be ordered by your healthcare team. You can use the discussion guide to help start a conversation about whether it may be right for your care plan.
No. It is used after diagnosis as part of ongoing care.
No. Signatera™ is used alongside imaging and other tools. It provides additional information to complement, not replace, standard care.
Signatera™ is covered by Medicare for monitoring disease progression, recurrence, or relapse in patients with:
- Stage II–IV and oligometastatic colorectal cancer (CRC)
- Muscle-invasive bladder cancer (MIBC)
- Stage II–IV breast cancer in the neoadjuvant setting
- Stage IIb and higher breast cancer
- Stage I–III non-small cell lung cancer (NSCLC)
- Stage II–IV ovarian, fallopian tube, or primary peritoneal cancer
- Monitoring response to immune checkpoint inhibitor therapy in patients with any solid tumor
Natera works with most commercial insurance plans. Financial assistance programs are available for eligible patients.
Test Limitations: Signatera™ can only be ordered by a physician or another authorized healthcare provider. This test provides information to be used alongside other clinical findings; it does not indicate definitively the presence or absence of cancer and it is not intended for diagnosis of cancer. It does not replace professional medical advice. Individual results and clinical management can vary. For additional information on test usage and limitations, visit Natera.com or speak with your doctor. This test is not designed to detect or report germline variation, nor does it infer hereditary cancer risk for the patient.
This is a Laboratory Developed Test performed in a high-complexity, CLIA-certified laboratory. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).